In the Spotlight
Read the recent blog post, "Recent Advances in Measuring Response to Immune Checkpoint Inhibitors,” highlighting studies published in our Journals: Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research, and Cancer Immunology Research
Read "Plasma Metabolites Predict Response to MEK Inhibition" in MCT's October issue. Using liquid chromatography/mass spectrometry (LC/MS)-based metabolomics and the MEK inhibitor RO4987655, 21 plasma metabolite markers of MEK inhibition in two sensitive BRAF mutant, human melanoma xenograft models were identified. Of these, Ang and colleagues found that on-treatment changes in the concentrations of 15 metabolites significantly predicted objective responses in patients with advanced melanoma treated with RO4987655. In patients with progressive disease, it was demonstrated that propionyl carnitine and amino acid levels increased; while in those patients that responded, phosphatidylcholines and sphingomyelin concentrations decreased. In addition, the pre-treatment levels of seven plasma metabolites (phosphatidylcholines and sphingomyelins) had significant prognostic value. Learn more in the latest issue of MCT.
Announcing the Cancer Epidemiology, Biomarkers & Prevention (CEBP) Focus: Rural Cancer Control call-for-papers. As rural cancer control is a national priority, CEBP will publish this Focus issue in advance of the AACR Annual Meeting 2018. Articles should address rural cancer health disparities across one aspect of the cancer control continuum including etiology, prevention, detection, diagnosis, treatment, or survivorship. The deadline for submissions is November 27th. Submit today.
Hot off the press! Read the just released Cancer Discovery article, Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
See the press release.